Evidence map›Paper›PMID 38451084›Full record

ArticleJournal of virology2024

The human adenovirus PI3K-Akt activator E4orf1 is targeted by the tumor suppressor p53.

Lilian Göttig, Simone Jummer, Luisa Staehler, Peter Groitl, Maryam Karimi, Paola Blanchette, Karin Kosulin, Philip E Branton, Sabrina Schreiner

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Detection of AdenoviralInternational journal of molecular sciences · 2026
    Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Lilian GöttigInstitute of Virology, School of Medicine, Technical University of Munich, Munich, Germany.ORCID 0009-0003-5288-5920
Simone JummerInstitute of Virology, School of Medicine, Technical University of Munich, Munich, Germany.
Luisa StaehlerInstitute of Virology, School of Medicine, Technical University of Munich, Munich, Germany.
Peter GroitlInstitute of Virology, School of Medicine, Technical University of Munich, Munich, Germany.
Maryam KarimiInstitute of Virology, School of Medicine, Technical University of Munich, Munich, Germany.
Paola BlanchetteDepartment of Biochemistry, McGill University, Montreal, Quebec, Canada.
Karin KosulinMolecular Microbiology, Children's Cancer Research Institute, Vienna, Austria.
Philip E BrantonDepartment of Biochemistry, McGill University, Montreal, Quebec, Canada.
Sabrina SchreinerInstitute of Virology, School of Medicine, Technical University of Munich, Munich, Germany.ORCID 0000-0002-5744-7159
Technical University of Munich · DEMcGill University · CACancer Research Institute of the Slovak Academy of Sciences · SKUniversity of Freiburg · DE

Funding

Deutsche Forschungsgemeinschaft (DFG) DEEP DV FOR5200Deutsche Forschungsgemeinschaft (DFG) Germany's 813 Excellence Strategy - EXC 2155 - project number 390874280Deutsche Forschungsgemeinschaft (DFG) Projektnummer 815 272983813 - TRR179
6 · The paper itself

Abstract

Human adenoviruses (HAdV) are classified as DNA tumor viruses due to their potential to mediate oncogenic transformation in non-permissive mammalian cells and certain human stem cells. To achieve transformation, the viral early proteins of the E1 and E4 regions must block apoptosis and activate proliferation: the former predominantly through modulating the cellular tumor suppressor p53 and the latter by activating cellular pro-survival and pro-metabolism protein cascades, such as the phosphoinositide 3-kinase (PI3K-Akt) pathway, which is activated by HAdV E4orf1. Focusing on HAdV-C5, we show that E4orf1 is necessary and sufficient to stimulate Akt activation through phosphorylation in H1299 cells, which is not only hindered but repressed during HAdV-C5 infection with a loss of E4orf1 function in p53-positive A549 cells. Contrary to other research, E4orf1 localized not only in the common, cytoplasmic PI3K-Akt-containing compartment, but also in distinct nuclear aggregates. We identified a novel inhibitory mechanism, where p53 selectively targeted E4orf1 to destabilize it, also stalling E4orf1-dependent Akt phosphorylation. Co-IP and immunofluorescence studies showed that p53 and E4orf1 interact, and since p53 is bound by the HAdV-C5 E3 ubiquitin ligase complex, we also identified E4orf1 as a novel factor interacting with E1B-55K and E4orf6 during infection; overexpression of E4orf1 led to less-efficient E3 ubiquitin ligase-mediated proteasomal degradation of p53. We hypothesize that p53 specifically subverts the pro-survival function of E4orf1-mediated PI3K-Akt activation to protect the cell from metabolic hyper-activation or even transformation.IMPORTANCEHuman adenoviruses (HAdV) are nearly ubiquitous pathogens comprising numerous subtypes that infect various tissues and organs. Among many encoded proteins that facilitate viral replication and subversion of host cellular processes, the viral E4orf1 protein has emerged as an intriguing yet under-investigated player in the complex interplay between the virus and its host. Nonetheless, E4orf1 has gained attention as a metabolism activator and oncogenic agent, while recent research is showing that E4orf1 may play a more important role in modulating the cellular pathways such as phosphoinositide 3-kinase-Akt-mTOR. Our study reveals a novel and general impact of E4orf1 on host mechanisms, providing a novel basis for innovative antiviral strategies in future therapeutic settings. Ongoing investigations of the cellular pathways modulated by HAdV are of great interest, particularly since adenovirus-based vectors actually serve as vaccine or gene vectors. HAdV constitute an ideal model system to analyze the underlying molecular principles of virus-induced tumorigenesis.

Indexed as

Adenovirus E4 ProteinsAdenoviruses, HumanPhosphatidylinositol 3-KinaseProto-Oncogene Proteins c-aktTumor Suppressor Protein p53Adenovirus Infections, HumanCell Line, TumorHEK293 CellsHumansOpen Reading FramesPhosphorylationUbiquitin-Protein LigasesVirus ReplicationAdenovirus E4 ProteinsPhosphatidylinositol 3-KinaseProto-Oncogene Proteins c-aktTP53 protein, humanTumor Suppressor Protein p53Ubiquitin-Protein LigasesE4orf1HAdVp53PI3K-Akttumor suppressor

Identifiers

PMID38451084
PMCPMC11019960
OpenAlexW4392561740

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.